Dynavax Technologies Corporation

Dynavax Technologies Corporation

Dynavax Technologies Corporation is a biopharmaceutical company that discovers and develops a pipeline of Toll-like Receptor (TLR) product candidates. The Company's product candidates include HEPLISAV, a hepatitis B vaccine; SD-101, a Phase Ib hepatitis C therapy; DV-601, a Phase Ib hepatitis B therapy; Universal Flu vaccine, a preclinical vaccine under a supply and option agreement with Novartis; AZD1419, a preclinical asthma therapy partnered with AstraZeneca AB, and DV1079, a preclinical autoimmune and inflammatory disease therapy partnered with GlaxoSmithKline. In January 2010, the Company completed the acquisition of Symphony Dynamo, Inc. (SDI) from Symphony Dynamo Holdings LLC. Pursuant to the acquisition SDI became a wholly owned subsidiary of the Company.

Contact Details

Office Address

Dynavax Technologies Corporation
2929 Seventh Street, Suite 100
Berkeley, CA, USA 94710
Phone: (510) 848-5100
Fax: (510) 848-1327


Chief Exec. Officer, Pres. and Exec. Director

Dr. Dino Dina

Chief Financial Officer and VP of Operations

Ms. Deborah A. Smeltzer

Business Reviews for Dynavax Technologies Corporation

Related Companies